amatuximab

{
  "id": "MLC-T-ONC-000435",
  "term": "amatuximab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of mesothelioma. Amatuximab binds to a protein called mesothelin, which is found on some cancer cells. Amatuximab may help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called anti-mesothelin monoclonal antibody MORAb-009 and MORAb-009.",
    "A chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed on many epithelial-derived cancer cells. Upon binding to the mesothelin antigen, amatuximab triggers an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing cells, resulting in cell lysis."
  ],
  "synonyms": [
    "anti-mesothelin monoclonal antibody MORAb-009",
    "MORAb-009",
    "immunoglobulin G1, anti-(mesothelin) (human-mouse monoclonal MORAb-009 heavy chain), disulfide with human-mouse monoclonal MORAb-009 kappa-chain, dimer"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/amatuximab/"
}